Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA4173933
Max Phase: Preclinical
Molecular Formula: C42H69N9O8
Molecular Weight: 828.07
Molecule Type: Small molecule
Associated Items:
ID: ALA4173933
Max Phase: Preclinical
Molecular Formula: C42H69N9O8
Molecular Weight: 828.07
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: CC(C)C[C@@H]1NC(=O)[C@@H](NC(=O)[C@H](Cc2ccc(O)cc2)NC(=O)[C@@H](N)CCCCN)CCCCCCC[C@@H](C(=O)N(C)C)NC(=O)[C@@H]2CCCN2C(=O)[C@H](C)NC1=O
Standard InChI: InChI=1S/C42H69N9O8/c1-26(2)24-33-38(55)45-27(3)41(58)51-23-13-17-35(51)40(57)47-32(42(59)50(4)5)16-10-8-6-7-9-15-31(37(54)49-33)46-39(56)34(25-28-18-20-29(52)21-19-28)48-36(53)30(44)14-11-12-22-43/h18-21,26-27,30-35,52H,6-17,22-25,43-44H2,1-5H3,(H,45,55)(H,46,56)(H,47,57)(H,48,53)(H,49,54)/t27-,30-,31-,32-,33-,34-,35-/m0/s1
Standard InChI Key: IXDGTQLHIYAWHI-FKBNJGARSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 828.07 | Molecular Weight (Monoisotopic): 827.5269 | AlogP: 0.70 | #Rotatable Bonds: 13 |
Polar Surface Area: 258.39 | Molecular Species: BASE | HBA: 10 | HBD: 8 |
#RO5 Violations: 2 | HBA (Lipinski): 17 | HBD (Lipinski): 10 | #RO5 Violations (Lipinski): 3 |
CX Acidic pKa: 9.42 | CX Basic pKa: 10.27 | CX LogP: -0.34 | CX LogD: -2.78 |
Aromatic Rings: 1 | Heavy Atoms: 59 | QED Weighted: 0.13 | Np Likeness Score: 0.58 |
1. Chen X, Liu L, Chen Y, Yang Y, Yang CY, Guo T, Lei M, Sun H, Wang S.. (2018) Cyclic Peptidic Mimetics of Apollo Peptides Targeting Telomeric Repeat Binding Factor 2 (TRF2) and Apollo Interaction., 9 (5): [PMID:29795768] [10.1021/acsmedchemlett.8b00152] |
Source(1):